Jaypirca: what changed in the evidence · Jaypirca · Dec 2023 – Dec 2025
Did the traditional approval cover the same patients as the accelerated approval?
No. The accelerated indication required two prior lines including a BTK inhibitor and a BCL-2 inhibitor; the traditional one covers relapsed or refractory patients treated with a covalent BTK inhibitor, the population of the randomized trial. The new wording replaced the old.
EphemerisX Research · Published · 4 source documents · 1 min read
Short answer
No; the indication was rewritten to match the confirmatory trial. The 2023 indication covered patients after at least two prior lines including a BTK inhibitor and a BCL-2 inhibitor. The 2025 indication covers relapsed or refractory patients previously treated with a covalent BTK inhibitor, with no BCL-2 inhibitor requirement; the trial excluded patients treated with a non-covalent BTK inhibitor. The endpoint also changed, from response rate to progression-free survival.
What the evidence shows
2023: who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
FDA · Dec 1, 2023 · p. 3, approved under accelerated approval based on response rate
FDA · Dec 1, 2023 · p. 3.
2025: the letter Updates the indication for Jaypirca (pirtobrutinib) for the treatment of adult patients with relapsed or refractory CLL/SLL who have previously been treated with a covalent BTK inhibitor
FDA · Dec 3, 2025 · p. 1. The FDA's announcement sets the two side by side: In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
FDA · Dec 3, 2025.
The trial's population: previously treated for CLL/SLL, including a covalent BTK inhibitor. Patients previously treated with a non-covalent BTK inhibitor were not permitted
FDA · Dec 3, 2025.
The current label carries the 2025 wording with no accelerated-approval statement: relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor
FDA · Oct 2, 2026 · p. 3. What the trial showed besides its endpoint: What did the CLL/SLL confirmatory trial show beyond progression-free survival?
Follow the thread
- What evidence supported Jaypirca's accelerated approval in CLL/SLL?Based on response rate
- What evidence allowed the FDA to convert Jaypirca's CLL/SLL approval to traditional approval?BRUIN CLL-321's population
- What did the CLL/SLL confirmatory trial show beyond progression-free survival?238 randomized patients
The documents, by date
The passages quoted
FDA-approved label, December 1, 2023 · page 3
JAYPIRCA is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. This indication is approved under accelerated approval based on response rate [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Open at the source →
FDA announcement, December 3, 2025
On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.Open at the source →
FDA announcement, December 3, 2025
Efficacy was evaluated in BRUIN-CLL-321 (NCT 04666038), a randomized, open-label, active-controlled trial. The trial randomized 238 patients who were previously treated for CLL/SLL, including a covalent BTK inhibitor. Patients previously treated with a non-covalent BTK inhibitor were not permitted.Open at the source →
FDA approval letter, December 3, 2025 · page 1
Updates the indication for Jaypirca (pirtobrutinib) for the treatment of adult patients with relapsed or refractory CLL/SLL who have previously been treated with a covalent BTK inhibitor.Open at the source →
FDA-approved label, October 2, 2026 · page 3
JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. 1.3 Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.Open at the source →